• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Adavosertib compared with active monitoring is potentially effective against TP53/RAS-mutant metastatic colorectal cancer.

byKassandra McFarlaneandSze Wah Samuel Chan
October 3, 2021
in Chronic Disease, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Patients on adavosertib had both increased progression-free survival and better tumor control, as compared to patients being actively monitored only.

2. Overall survival was not affected by adavosertib as compared to active monitoring, but a subgroup analysis showed an increase in survival for patients with a left-sided primary compared to those with a right-sided primary.

Evidence Rating Level: 2 (Good)

Study Rundown: Metastatic colorectal cancer patients with the TP53/RAS-mutant are considered a worse prognosis group as compared to either mutation subgroup alone. This study hypothesized that the TP53/RAS mutation would be sensitive to a WEE1 kinase inhibitor, adavosertib (AZD1775). Comparison of progression-free survival (PFS), overall survival (OS), and tumor control between a treatment arm (adavosertib) and a control arm (active monitoring) showed that both PFS and tumor control were increased with administration of adavosertib in both intention-to-treat (ITT) and per-protocol-analysis (PPA). Overall survival was similar between study groups. Secondary outcomes of toxicity were increased in the treatment group as compared to active monitoring. Adverse events included nausea, vomiting, diarrhea, and fatigue. A major limitation of this study is that it was unblinded in order to provide supportive care for those on adavosertib. Other studies have shown that antiemetics were required to control the severe nausea and vomiting associated with this treatment. Further limitations include the lack of generalizability of results to the entire TP53/RAS-mutant group because the eligibility requirements of this study necessitated stability following induction chemotherapy, thereby excluding patients of this subgroup with the worst prognosis. In general, however, adavosertib provides increased progression-free survival and tumor control in patients with TP53/RAS-mutant mCRC.

Click to read the study in JCO

Relevant Reading: MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

In-Depth [randomized controlled trial]: This phase 2, open-label, randomized trial of 69 patients with TP53/RAS-mutant mCRC comparing adavosertib treatment to active monitoring (AM) on outcomes of progression-free survival (PFS), overall survival (OS), and tumor control. A 2:1 ratio was used to randomize patients to the study arm compared to AM. Eligibility for inclusion in this FOCUS4-C study included adult patients with both the TP53 and RAS somatic mutations of mCRC who were stable at 16 weeks post-chemotherapy induction, as assessed by CT. Patients in the treatment arm received antiemetic therapy including oral dexamethasone as well as oral 5HT3 antagonist. Patients remained on treatment until disease progression or severe toxicity. Intention-to-treat analysis of PFS was consistent with the PPA (unadjusted HR = 0.55; 95% CI, 0.32 to 0.94; p=0.032; adjusted HR = 0.40; 95% CI, 0.21 to 0.75; p=0.0051). Tumor control was increased in the treatment arm. No overall survival benefit was noted (unadjusted HR = 0.79; 95% CI, 0.42 to 1.48, p=0.47; adjusted HR = 0.92; 95% CI, 0.44 to 1.94, p=0.93), however, a subgroup analysis comparing OS based on the sidedness and compared to active monitoring showed an increase in OS for patients with left-sided tumors (adjusted HR = 0.37; 95% CI, 0.15 to 0.87) and a decreased OS for patients with right-sided tumors (HR = 6.5; 95% CI, 0.72 to 6.43) with caution about the interpretation given the low number of events. The level of reported toxicity, while higher in the treatment arm, was mostly low grade. Between 2-10% of the patients in the treatment arm had grade 3 or higher, while none of the AM group did.

RELATED REPORTS

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer

Higher abundance of dietary sulfur-reducing microbes was associated with increased risk of colorectal cancer

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colorectal cancertargeted therapyTP53 gene
Previous Post

Prostate-Specific Membrane Antigen Positron Emission Tomography can be used to detect pelvic lymph nodes in prostate cancer

Next Post

Tips to Manage Your Mental Health During the COVID-19 Outbreak

RelatedReports

Oophorectomy associated with reduced cancer risk and all-cause mortality for BRCA1/2 patients
Oncology

Pembrolizumab did not show overall survival benefit in patients with microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer

April 18, 2022
Noninvasive imaging method detects and evaluates size of metastases
Chronic Disease

Addition of atezolizumab to capecitabine + bevacizumab is not clinically beneficial in the treatment of refractory metastatic colorectal cancer

February 25, 2022
Normal renal ultrasound only rules out high grade vesicoureteral reflux in infants
Gastroenterology

Higher abundance of dietary sulfur-reducing microbes was associated with increased risk of colorectal cancer

January 4, 2022
Provision of medically-tailored meals linked with lower admissions and medical spending
Wellness

Wellness Check: Nutrition

December 30, 2021
Next Post

Tips to Manage Your Mental Health During the COVID-19 Outbreak

Patients with low back pain or pain at multiple sites at highest risk for chronic opioid use

United States providers increased prescribing of buprenorphine/naloxone

Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress

Methylphenidate associated with short-term reduction in symptoms of apathy in patients with Alzheimer disease

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Vitamin and mineral supplementation associated with minimal to no benefit in the primary preventing of cardiovascular disease and cancer – US Preventative Services Task Force
  • RSVpreF vaccine prevents symptomatic respiratory syncytial virus infection
  • Incidence of Kawasaki disease found to be lower during the COVID-19 pandemic in the United States
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.